New Delhi: N'ịzaghachi atụmatụ Fresenius Medical Care, Kọmitii Ọkachamara Pụrụ Iche (SEC) nke Central Drugs Standard Control Organisation (CDSCO) akwadola ụlọ ọrụ ahụ ka o nye ihe kpatara nkwenye yana data nnwale ahụike nke usoro nke atọ nke calcium chloride dihydrate na data nlekota mgbe ahịa gasịrị site na mba ndị akwadoro maka ịtụlekwu.
Ụlọ ọrụ ahụ tinyere akwụkwọ maka imepụta ma ree ihe ngwọta calcium chloride dihydrate na mkpokọta nke 100 mmol/L, nke a na-eji maka "ọgwụgwọ nnọchi calcium na ọgwụgwọ nnọchi akụrụ na-aga n'ihu (CRRT), ọgwụgwọ dialysis na-adịghị arụ ọrụ nke ọma (CLED) na mgbanwe plasma ọgwụgwọ (TPE) na citrate anticoagulation. Ngwaahịa a dabara adaba maka ndị okenye na ụmụaka" ma kwuo ihe kpatara e ji ewepụ ya na nnwale ahụike nke usoro nke atọ na nke usoro nke anọ.
Kọmitii ahụ kwuru na a kwadoro ngwaahịa a na mba Yuropu dịka Pọtugal, United Kingdom, Brazil, Switzerland, France na Denmark.
Ihe mejupụtara calcium chloride dihydrate bụ CaCl2 2H2O, nke bụ calcium chloride nke nwere molekul mmiri abụọ kwa otu nke calcium chloride. Ọ bụ ihe kristal ọcha, nke a na-agbaze ngwa ngwa na mmiri ma na-eme ka ọ dị ọcha, ya bụ, ọ nwere ike ịmịkọrọ mmiri site na ikuku.
Calcium chloride dihydrate bụ ihe mejupụtara nke enwere ike iji dị ka usoro ihe mgbaze iji gbazee chitin mgbe agbazere na methanol. Ọ na-arụ ọrụ dị mkpa n'imebi nhazi kristal nke chitin ma nwee ọtụtụ ojiji na ngalaba kemistri.
Na nzukọ SEC Nephrology nke e mere na Mee 20, 2025, ndị otu ahụ nyochachara atụmatụ iji kwado mmepụta na ire ahịa nke 100 mmol/L calcium chloride dihydrate infusion solution maka ojiji na "ọgwụgwọ nnọchi calcium na ọgwụgwọ nnọchi akụrụ na-aga n'ihu (CRRT), dialysis na-aga n'ihu na-adịghị arụ ọrụ (kwa ụbọchị) (SLEDD), na mgbanwe plasma ọgwụgwọ (TPE) na citrate anticoagulation. A na-egosi ngwaahịa a na ndị okenye na ụmụaka" ma nye ihe akaebe maka mwepụ na nnwale ahụike nkebi nke atọ na nke anọ.
Mgbe e nwesịrị mkparịta ụka zuru ezu, kọmitii ahụ tụrụ aro ka e nye kọmitii ahụ ihe ndabere maka nkwenye, yana data nnwale ahụike nke ọkwa nke atọ na data nlekota mgbe ahịa gasịrị site na mba ndị kwadoro ọgwụ ahụ, ka e leba anya n'ihe ndị ọzọ.
Gụọkwa: Òtù CDSCO Kwadoro Ndebanye aha emelitere maka Myozyme nke Sanofi, rịọkwa ka e nyochaa iwu.
Dr. Divya Kolin bụ onye gụsịrị akwụkwọ na PharmD, nwere ahụmịhe dị ukwuu n'ọgwụ na ụlọ ọgwụ, yana nkà nchọpụta na ọgwụgwọ dị mma. Ọ rụkwara ọrụ dịka onye na-ere ọgwụ oncology na ngalaba oncology na Mysore Medical College and Research Institute. Ọ na-arụ ọrụ ugbu a na nyocha ahụike na njikwa data ahụike. Ọ na-arụ ọrụ na Medical Dialogue kemgbe Jenụwarị 2022.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
Nnyocha ABYSS chọpụtara na ịkwụsị beta-blockers mgbe myocardial infarction butere mmụba na ọbara mgbali elu, ọnụego obi, na ihe ọjọọ gbasara obi: ...